JP2014195454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014195454A5 JP2014195454A5 JP2014087047A JP2014087047A JP2014195454A5 JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5 JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- receptor
- polypeptide
- protease
- hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 11
- 108020003175 receptors Proteins 0.000 claims 11
- 108091005804 Peptidases Proteins 0.000 claims 10
- 239000004365 Protease Substances 0.000 claims 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 8
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 8
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 8
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 8
- 101710142969 Somatoliberin Proteins 0.000 claims 8
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 8
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 8
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 8
- 208000010916 pituitary tumor Diseases 0.000 claims 8
- 230000005945 translocation Effects 0.000 claims 7
- 108010056088 Somatostatin Proteins 0.000 claims 6
- 231100000065 noncytotoxic Toxicity 0.000 claims 6
- 230000002020 noncytotoxic effect Effects 0.000 claims 6
- 108010055044 Tetanus Toxin Proteins 0.000 claims 5
- 102000005157 Somatostatin Human genes 0.000 claims 4
- 210000001163 endosome Anatomy 0.000 claims 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 4
- 229960000553 somatostatin Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010051479 Bombesin Proteins 0.000 claims 2
- 108010073466 Bombesin Receptors Proteins 0.000 claims 2
- 101800001586 Ghrelin Proteins 0.000 claims 2
- 108010016122 Ghrelin Receptors Proteins 0.000 claims 2
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 claims 2
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 claims 2
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 claims 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 claims 2
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 102000056271 Prolactin-releasing peptide receptors Human genes 0.000 claims 2
- 108700024163 Prolactin-releasing peptide receptors Proteins 0.000 claims 2
- 101150056450 UTS2R gene Proteins 0.000 claims 2
- 108010011107 Urotensins Proteins 0.000 claims 2
- 210000000172 cytosol Anatomy 0.000 claims 2
- 230000028023 exocytosis Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 claims 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000000813 peptide hormone Substances 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 1
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000033052 Somatotropic adenoma Diseases 0.000 claims 1
- 102000012327 Urotensin II receptors Human genes 0.000 claims 1
- 108050002984 Urotensin II receptors Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000007375 bacterial translocation Effects 0.000 claims 1
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 claims 1
- 201000010430 hormone producing pituitary cancer Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000007377 viral translocation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0810782.3A GB0810782D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of cancers |
| GB0810782.3 | 2008-06-12 | ||
| GB0810785A GB0810785D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of neuroendocrine diseases |
| GB0810785.6 | 2008-06-12 | ||
| GB0820884A GB0820884D0 (en) | 2008-11-14 | 2008-11-14 | Suppression of neuroendocrine diseases |
| GB0820884.5 | 2008-11-14 | ||
| GB0820965.2 | 2008-11-17 | ||
| GB0820965A GB0820965D0 (en) | 2008-11-17 | 2008-11-17 | Suppression of cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Division JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014195454A JP2014195454A (ja) | 2014-10-16 |
| JP2014195454A5 true JP2014195454A5 (https=) | 2014-11-27 |
| JP5891258B2 JP5891258B2 (ja) | 2016-03-22 |
Family
ID=41417177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Active JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
| JP2014087047A Expired - Fee Related JP5891258B2 (ja) | 2008-06-12 | 2014-04-21 | 神経内分泌疾患の抑制 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Active JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110171191A1 (https=) |
| EP (3) | EP3590956A1 (https=) |
| JP (2) | JP5728380B2 (https=) |
| KR (1) | KR101642363B1 (https=) |
| CN (2) | CN102112145B (https=) |
| AU (1) | AU2009259033B2 (https=) |
| BR (1) | BRPI0915888E2 (https=) |
| CA (1) | CA2727082C (https=) |
| ES (2) | ES2614990T3 (https=) |
| IL (1) | IL209855A (https=) |
| WO (1) | WO2009150469A2 (https=) |
| ZA (1) | ZA201008536B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| CA2727082C (en) * | 2008-06-12 | 2019-02-26 | Syntaxin Limited | Fusion proteins for use in suppression of acromegaly |
| GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| ES2711526T3 (es) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| KR102762958B1 (ko) | 2014-09-15 | 2025-02-04 | 클리프톤 라이프 사이언시즈 엘엘씨 | 위장관췌장 신경내분비 신생물의 진단을 위한 조성물, 방법 및 키트 |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016061583A1 (en) * | 2014-10-17 | 2016-04-21 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| JP7118055B2 (ja) | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| JP7328153B2 (ja) * | 2017-05-31 | 2023-08-16 | ナポ ファーマシューティカルズ インク． | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 |
| TWI822723B (zh) | 2018-01-29 | 2023-11-21 | 英商艾普森生物製藥有限公司 | 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途 |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
| CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
| CN113257370B (zh) * | 2021-05-12 | 2022-09-02 | 中国医学科学院北京协和医院 | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 |
| WO2025155896A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
| US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
| DE2860734D1 (en) | 1977-06-08 | 1981-09-03 | Merck & Co Inc | Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them |
| US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
| LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
| JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
| US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
| US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
| US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
| US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
| US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
| EP0083305B1 (de) | 1981-12-24 | 1985-07-10 | Ciba-Geigy Ag | Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung |
| FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
| US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4632979A (en) | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
| US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
| US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4803261A (en) | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| NL194729C (nl) | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
| US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
| WO1989002897A1 (en) | 1987-09-24 | 1989-04-06 | The Administrators Of The Tulane Educational Fund | Therapeutic peptides |
| US5084555A (en) | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
| EP0329295A1 (en) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
| ZA895838B (en) | 1988-08-18 | 1991-03-27 | Syntex Inc | Pharmaceutical compounds |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| MC2144A1 (fr) | 1988-10-14 | 1992-02-19 | Univ Tulane | Peptides therapeutiques |
| US5171835A (en) | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
| CA2053250A1 (en) | 1989-04-26 | 1990-10-27 | David H. Coy | Linear somatostatin analogs |
| WO1991009056A1 (en) | 1989-12-08 | 1991-06-27 | The Administrators Of The Tulane Educational Fund | Octapeptide analogs of somatostatin having threonine at the sixth position |
| DK0450461T3 (da) | 1990-04-06 | 1995-10-23 | Univ Tulane | LHRH-analoger |
| CA2082059A1 (en) | 1990-05-04 | 1991-11-05 | David H. Coy | Synthetic grf analogs |
| JPH05506862A (ja) | 1990-05-09 | 1993-10-07 | ジ・アドミニストレイターズ・オブ・ザ・トゥーラン・エデュケイショナル・ファンド | 環状および鎖状の治療用ペプチド |
| IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
| US6083915A (en) | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
| US5240561A (en) | 1992-02-10 | 1993-08-31 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| US5656727A (en) | 1992-09-15 | 1997-08-12 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
| WO1994011397A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
| AU5668894A (en) | 1992-11-13 | 1994-06-08 | The Administrators Of The Tulane Eductional Fund | Ghrh agonists |
| GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| RO117259B1 (ro) | 1993-08-09 | 2001-12-28 | Biomeasure Inc. | Derivaţi peptidici, terapeutici |
| US5550212A (en) | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| AUPM985694A0 (en) | 1994-12-02 | 1995-01-05 | Farmer, Mostyn | Golf training aid |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| ES2124496T3 (es) | 1995-03-13 | 1999-02-01 | Biomeasure Inc | Analogos de bombesina. |
| EP0820296A4 (en) | 1995-04-14 | 1999-06-30 | Univ Tulane | ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US5942489A (en) | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US5968903A (en) | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
| DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
| IL140837A0 (en) | 1998-07-30 | 2002-02-10 | Sod Conseils Rech Applic | Method of using lanreotide, a somatostatin analogue |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| CA2376506C (en) | 1999-06-04 | 2014-07-22 | Dean Sadat-Aalaee | Neuromedin b and somatostatin receptor agonists |
| ATE348178T1 (de) * | 1999-08-25 | 2007-01-15 | Allergan Inc | Aktivierbare rekombinante neurotoxine |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| EP1599213A4 (en) * | 2003-02-24 | 2009-07-15 | Ira Sanders | CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES |
| TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE602005011458D1 (de) * | 2004-09-01 | 2009-01-15 | Allergan Inc | Abbaubare clostridientoxine |
| AU2005311086B2 (en) * | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007272515B2 (en) * | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| CA2727082C (en) * | 2008-06-12 | 2019-02-26 | Syntaxin Limited | Fusion proteins for use in suppression of acromegaly |
| CN102083451A (zh) * | 2008-06-12 | 2011-06-01 | 赛恩泰新公司 | 癌症的抑制 |
| US10057187B1 (en) | 2015-05-27 | 2018-08-21 | Amazon Technologies, Inc. | Dynamic resource creation to connect client resources in a distributed system |
-
2009
- 2009-06-11 CA CA2727082A patent/CA2727082C/en not_active Expired - Fee Related
- 2009-06-11 ES ES09762018.1T patent/ES2614990T3/es active Active
- 2009-06-11 AU AU2009259033A patent/AU2009259033B2/en not_active Ceased
- 2009-06-11 WO PCT/GB2009/050665 patent/WO2009150469A2/en not_active Ceased
- 2009-06-11 CN CN200980130069.3A patent/CN102112145B/zh not_active Expired - Fee Related
- 2009-06-11 ES ES13179177T patent/ES2750651T3/es active Active
- 2009-06-11 CN CN201410295607.7A patent/CN104328100B/zh not_active Expired - Fee Related
- 2009-06-11 EP EP19175007.4A patent/EP3590956A1/en active Pending
- 2009-06-11 US US12/996,643 patent/US20110171191A1/en not_active Abandoned
- 2009-06-11 JP JP2011513056A patent/JP5728380B2/ja active Active
- 2009-06-11 EP EP13179177.4A patent/EP2719392B1/en active Active
- 2009-06-11 KR KR1020117000251A patent/KR101642363B1/ko not_active Expired - Fee Related
- 2009-06-11 BR BRC10915888A patent/BRPI0915888E2/pt not_active IP Right Cessation
- 2009-06-11 EP EP09762018.1A patent/EP2310028B1/en active Active
-
2010
- 2010-11-29 ZA ZA2010/08536A patent/ZA201008536B/en unknown
- 2010-12-08 IL IL209855A patent/IL209855A/en not_active IP Right Cessation
-
2014
- 2014-04-21 JP JP2014087047A patent/JP5891258B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014195454A5 (https=) | ||
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| NZ599259A (en) | Mycobacterial vaccines | |
| MX2022001134A (es) | Proteinas quimericas de factor viii y usos de estas. | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| MY184163A (en) | Transgene genetic tags and methods of use | |
| NZ745324A (en) | Vaccines and vaccine components for inhibition of microbial cells | |
| NZ702145A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
| WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| NZ628756A (en) | Immunogens for hiv vaccination | |
| ES2454773T3 (es) | Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN | |
| WO2011156619A3 (en) | Vaccine and methods to reduce campylobacter infection | |
| WO2016130628A8 (en) | Griffithsin mutants | |
| Zelena et al. | Escherichia coli as a production host for novel enzymes from basidiomycota | |
| WO2008151633A3 (en) | Vectors for vaccines against lentivirus infections | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| MX2023002413A (es) | Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. | |
| EP4717776A3 (en) | Polypeptide conjugates for intracellular delivery of nucleic acids | |
| WO2010040847A3 (en) | Recombinant protein bodies as immunogen-specific adjuvants | |
| HK1250992A1 (zh) | 表皮生长因子受体变体iii-间皮素融合物及其使用方法 | |
| MX339559B (es) | Conjugados de igf-i poli(etilenglicol). | |
| GB2498323A (en) | Generation of antigenic virus-like particles through protein-protein linkages |